SOST and bone disorder: Previous studies have reported that serum DKK-1 and SOST are not affected by treatment with anti-TNF agents in spondylopathies and are only modified depending on age [31], while other studies report that in patients with AS treated with TNF inhibitors, serum levels of DKK-1 are increased [32]; the results remain controversial.